Item 1.02 Termination of a Material Definitive Agreement
On
Upon termination of the License Agreement and the Merger Agreement, the Company regains all rights to develop the IBD Synthetic Biotic medicines previously developed with AbbVie pursuant to the License Agreement and the Merger Agreement as well as new IBD Synthetic Biotic medicines for all effectors targeting IBD.
The foregoing description of the License Agreement is not complete and is
qualified in its entirety by reference to the full text of the License
Agreement, a copy of which is filed as Exhibit 10.27 to the Company's Annual
Report on Form 10-K for the year ending
A copy of the press release announcing the termination of the License Agreement and the Merger Agreement is filed as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press Release datedMay 21, 2020
--------------------------------------------------------------------------------
© Edgar Online, source